Hospital-Treated Gram-Negative Infections – Epidemiology – Emerging Markets
Clarivate Epidemiology’s coverage of hospital-treated gram-negative infections (HT–GNIs) comprises epidemiological estimates of nine types of infections in the emerging pharmaceutical markets (Brazil, rural China, urban China, rural India, urban India, Mexico, Russia, South Korea, and Turkey). The nine kinds of infections are urinary tract infections (UTIs), bloodstream infections (BSIs), complicated intra-abdominal infections (cIAIs), complicated skin and skin structure infections (cSSSIs), surgical-site infections (SSIs), nosocomial pneumonia (NP), hospital-acquired pneumonia (HAP), healthcare-acquired pneumonia (HCAP), and ventilator-associated pneumonia (VAP). We report the incidence of HT–GNIs for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 10 years for the emerging pharmaceutical markets.
Clarivate Epidemiology’s HT–GNI forecast will answer the following question:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of HT–GNIs over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts 42 HT–GNI patient populations, including the following:
- Diagnosed gram-negative UTI hospitalization events due to E. coli.
- Diagnosed gram-negative SSI hospitalization events due to Pseudomonas spp.
- Diagnosed gram-negative BSI hospitalization events due to E. coli.
- Diagnosed gram-negative cSSSI hospitalization events due to Acinetobacter spp.
- Diagnosed gram-negative cIAI hospitalization events due to Klebsiella spp.
- Diagnosed gram-negative NP hospitalization events due to Pseudomonas spp.
Note: Coverage may vary by country and region.
Table of contents
- Hospital-Treated Gram-Negative Infections - Epidemiology - Emerging Markets
- Epidemiology data
- Methods
- Literature review (studies included in/excluded from the analyses of hospital-treated gram-negative infections)
- Diagnosed urinary tract infection events
- Diagnosed bloodstream infection events
- Diagnosed nosocomial pneumonia events
- Diagnosed complicated intra-abdominal infection events
- Diagnosed surgical-site infection events
- Diagnosed complicated skin and skin structure infection events
- Pathogen distribution
- Risk / protective factors applied to disease forecast models
- Reference Materials
